Posts by Admin BioAlps
Lunaphore collaborates with PerkinElmer
The Swiss start-up announced on 20 March that it will collaborate with the American multinational corporation to develop staining and analysis solutions for tumor samples. Read the full press release here
Read MoreLa 2ème édition d’Orthomanufacture
Fort du succès enregistré à St Etienne en juin dernier, Orthomanufacture récidive à Yverdon-les-Bains les 20 et 21 juin 2018. DeviceMed a interviewé les deux organisateurs, Philippe Planche et Olivier Vecten, pour faire le point sur cette deuxième édition. Article complet
Read MoreLundbeck to acquire Prexton Therapeutics
This acquisition will add foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease Attachment Lundbeck announced on 16 March 2018 that it will acquire Prexton Therapeutics for up to EUR 905 million. Full press release
Read MoreLe Challenge Debiopharm Inartis
La qualité de vie du patient en cours de traitement “Qui pourra changer le monde dans lequel nous vivons?” «Construisons ensemble notre futur». C’est avec cette ambition et avec le désir de soutenir concrètement les personnes en traitement que le groupe pharmaceutique Debiopharm Group et la Fondation Inartis ont le plaisir de lancer un appel…
Read MoreLuc Stoppini raconte son Prix BioAlps
Prix BioAlps 2017 : la récompense d’une carrière Article du magazine HEPIA news – Mars 2018
Read MoreGlenmark Pharmaceuticals S.A. to invest in new Translational Research Group @ Biopôle
Glenmark Pharmaceuticals announces it will enhance its capabilities in translational research by opening a new discovery centre at the Biopôle campus of Lausanne. View full article
Read MoreKick-off Medtech Accelerator at EPFL Innovation Park
Monday 12 March @ 17:30, at room Neptune, Building C of EPFL Innovation Park Learn more about La Forge’s new expert coaching programs for a selection of verticals. The first vertical acceleration track will be dedicated for Medtech related projects! Don’t miss your chance and sign up to the event here. Programme information
Read MoreCompugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of An
Selexis SA announces that Compugen Ltd. has taken a license to the Selexis SUREtechnology Platform™ for use in generating high-performance research cell banks (RCBs). All the information you wish to know about this news is accessible here.
Read MoreSelexis SA and Xencor sign 4 Commercial License Agreements
On 26 February, Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, today announced that it has signed four commercial license agreements (CLAs) with Xencor, Inc. (NASDAQ: XNCR), a…
Read MoreUNIBE – Des cultures cellulaires en 3D contre les résistances des cancers
La médecine de précision, c’est-à-dire la mise au point de traitements personnalisés, est un objectif majeur de la recherche moderne contre le cancer. Une équipe de chercheurs de l’université de Berne a développé des cultures cellulaires en 3D (dits organoïdes) en collaboration étroite avec le Netherlands Cancer Institute (NKI) d’Amsterdam et l’Hubrecht Institut d’Utrecht afin…
Read More